Evidence map›Paper›PMID 41142425›Full record

ReviewMaterials today. Bio2025

Huan Wang, Xiying Wu, Junji Wang, Xiaoyi Wang, Ying Lu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huan WangDepartment of Pharmaceutical Sciences, School of Pharmacy, Naval Medical University, Shanghai, China.
Xiying WuShanghai Skin Disease Hospital, School of Medicine Tongji University, Shanghai, China.
Junji WangDepartment of Pharmaceutical Sciences, School of Pharmacy, Naval Medical University, Shanghai, China.
Xiaoyi WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China.
Ying LuDepartment of Pharmaceutical Sciences, School of Pharmacy, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid-based nanomedicines (LBNMs) represent a transformative frontier in improving drug bioavailability and achieving spatiotemporally precise delivery of therapeutic agents. However, establishing robust

Indexed as

DissolutionIn vitro-in vivo correlationIn vivo delivery processLipid-based nanomedicinesProtein coronas

Identifiers

PMID41142425
PMCPMC12549719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.